Dr. Liu highlights that sequentially administering ADCs remains active if clinicians change the cytotoxic payload, even when targeting the identical receptor. Conversely, emerging prospective breast cancer trials indicate that sequencing a topoisomerase I inhibitor ADC directly after another yields very low antitumor response rates.
Next-generation topoisomerase I payload ADCs are showing up to 50% response rates in platinum-resistant ovarian cancer without requiring high biomarker expression. Unlike mirvetuximab or trastuzumab deruxtecan, these emerging agents could broaden clinical accessibility to broader patient populations without upfront IHC biomarker stratification.
Next-generation dual-payload ADCs combine distinct mechanisms, such as microtubule inhibitors with topoisomerase I inhibitors or ATR inhibitors, effectively acting as targeted combination chemotherapy. Dr. Liu notes their success will depend heavily on whether efficacy outweighs toxicities caused by free payloads circulating systemically.
Tumors can overexpress Cyclin E1 protein without genomic CCNE1 amplification, driving chronic G1/S progression and replication stress. This leaves malignant cells strictly dependent on the G2/M checkpoint for survival, where WEE1 inhibitors like azenosertib demonstrate promising 30% to 35% response rates in clinical evaluation.
High-grade serous ovarian cancer exhibits high chromosomal instability, leaving cells vulnerable when mitotic chromosome alignment fails. Inhibiting KIF18A, a kinesin motor that centers chromosomes on the metaphase plate, prevents even segregation and forces tumor cells into mitotic catastrophe and subsequent cell death.
In KRAS-mutant low-grade serous ovarian cancer, blocking RAS-RAF-MEK signaling triggers compensatory FAK pathway upregulation as an escape mechanism. Combining the RAF/MEK clamp avutametnib with FAK inhibitor defactinib abrogates this bypass resistance, demonstrating notable activity that recently secured accelerated FDA approval.
